Related Experiment Video

Updated: Jun 19, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1

Jing Zhang1, Yan Li, Liang Guo

  • 1Institute of Medicinal Biotechnology, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.

Cancer Biology & Therapy
|October 27, 2009
PubMed

Insights

Beta-carboline derivatives, like DH166, show anticancer potential by inhibiting Polo-like kinase 1 (PLK1). This novel mechanism targets cell division, offering new strategies for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Targeting multiple pathways simultaneously offers a promising strategy for treating complex diseases like cancer.
  • Beta-carboline derivatives exhibit anticancer properties, potentially by inhibiting enzymes crucial for cell division.
  • Polo-like kinase 1 (PLK1) is a key regulator of cell proliferation and a significant target for anticancer drug development.

Purpose of the Study:

  • To investigate the potential of beta-carboline derivatives as inhibitors of Polo-like kinase 1 (PLK1).
  • To elucidate the mechanism by which DH166, a beta-carboline derivative, affects cancer cell proliferation.
  • To establish PLK1 inhibition as a novel mechanism for the antitumor activity of beta-carboline derivatives.

Main Methods:

  • Yeast growth assays using temperature-sensitive mutants and wild-type strains.
  • In vitro kinase assays to determine PLK1 inhibition kinetics.
  • Molecular docking studies based on the crystal structure of PLK1.
  • Analysis of cancer cell proliferation, cell cycle progression, and apoptosis.

Main Results:

  • DH166 demonstrated more profound inhibition of a yeast PLK1 homologue (Cdc5) in temperature-sensitive mutants compared to wild-type cells.
  • DH166 was identified as an ATP-competitive inhibitor of purified PLK1 at low micromolar concentrations.
  • DH166 treatment led to cancer cell proliferation arrest, mitotic spindle abnormalities, cyclin B1 accumulation, and apoptosis, consistent with PLK1 downregulation.

Conclusions:

  • The beta-carboline derivative DH166 is a potent inhibitor of Polo-like kinase 1 (PLK1).
  • DH166 exhibits anticancer effects by inducing mitotic arrest and apoptosis, mediated through PLK1 inhibition.
  • PLK1 inhibition represents a newly identified mechanism contributing to the cytotoxic effects of beta-carboline derivatives against tumor cells.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...